Immatics’ Post

The speakers of RICT 2024 are announced! The programme will feature 19 plenary lectures and 6 short lectures focusing on "Interfacing Chemical Biology and Drug Discovery". TOPICS - Chemistry in Living Systems and Chemical Biology - Induced Proximity Including Degraders - Next Generation Cancer Therapeutics - New Modalities for Drug Discovery - Enabling Technologies - Recent Trends in Neurodegenerative Diseases Drug Development - First Disclosures of Clinical Candidates and Cases Studies - Breakthroughs in Deep Learning, CryoEM and their Impact on Drug Discovery Moreover, a special career session will be organised with industrial and academic participants. GRANTS A limited number of grants will be funded by the SCT and Corporate Sponsors with the aim to support the participation of young academic scientists. CALL FOR ABSTRACTS A poster session will provide the opportunity for all participants to present their current results. Abstract submission deadline:  May 14, 2024. Poster prizes will be attributed at the end of the meeting. CALL FOR AWARD APPLICATIONS 2 Prizes will be awarded by Galapagos and Evotec in partnership with the SCT. The 2 awardees will be invited to give a lecture during RICT 2024. Deadline for application submission: March 15, 2024 Visit www.rict2024.org for more information #MedChem #MedicinalChemistry #DrugDiscovery

Exciting News Alert! I'm thrilled to share groundbreaking research led by Professor John Moses and his team at Cold Spring Harbor Laboratory (CSHL) in the realm of drug discovery! Their innovative process, Accelerated SuFEx Click Chemistry (ASCC), has enabled the rapid synthesis of over 150 new compounds, including derivatives of complex natural molecules like combretastatin A4 and dapsone. Even more astonishing, some of these compounds have shown effectiveness against cancer cells resistant to standard chemotherapy and bacteria resistant to dapsone. This breakthrough not only holds promise for developing novel treatments but also signifies a potential game-changer in overcoming drug resistance. Read more about this fascinating research here: #Chemistry #DrugDiscovery #Innovation #Research #Science #ASCC #ClickChemistry https://lnkd.in/eE2VyKFN

£900M investment for a new #lifesciences hub (Elevate Quarter) in Stevenage, UK - I am sure many of you will have seen this, but it's too good to not share! https://lnkd.in/dak6JnRh This is a great advancement for UK science and, among other things, is the perfect location to push the cell & gene therapy sector into the future - Perhaps some of the biggest challenges of #ATMP manufacturing (scalability, cost, maintaining safety) will be solved at the Elevate Quarter over the next few years? 💡🧬 - Up to 5,000 new jobs. - First phase set to complete at the end of 2025. - Adjacent to GSK, Cell & Gene Therapy Catapult and Stevenage Bioscience Catalyst. - 1.6M sq ft of R&D, GMP and office space. How do you think this is going to impact the UK life-science sector? #biotechnology #celltherapy #genetherapy #cellandgenetherapy #drugdiscovery #biopharmaceuticals #pharmaceutical #ukbusiness #gmp #elevatequarter

#excitingnews #therapeutics #ClickChemistryTakesCenterStage I am thrilled to share this groundbreaking development in the field of cancer therapies! Shasqi , a pioneering biotech company, has joined forces with Johnson & Johnson Enterprise Innovation to leverage the power of click chemistry in targeting tumors. The potential of click chemistry therapeutics has caught the attention of investors and big pharma alike, and it's no surprise why! Shasqi's click-activated drug delivery system has shown remarkable progress, successfully passing the first human safety trials and advancing to a phase 2 clinical trial. As someone deeply invested in the advancement of medical science, I couldn't be more excited about this collaboration and its potential to transform cancer treatment. Let's keep a close eye on the progress and wish them success in this noble quest to improve patients' lives. #ScienceNews #CancerTherapies #MedicalAdvancements #ClickChemistry #BiotechInnovation #ClinicalTrials #HealthcareHeroes

Dear LinkedIn Network,   I am thrilled to announce that I have been invited as a speaker at two prestigious international conferences: the 4th Edition of Chemistry World Conference in Paris, France, and the 6th International Conference on Chemistry in Rome, Italy! 🎤✨ I will be presenting on the topic: "Identification of Transthyretin Tetramer Kinetic Stabilizers to Inhibit Retinol-dependent RBP4-TTR Interaction: Novel Therapeutics for Macular Degeneration and Transthyretin Amyloidosis." 🧪🔬   I am honored for this opportunity to share insights into groundbreaking research. Looking forward to engaging in discussions and connecting with fellow professionals in the field. Stay tuned for updates and insights from these conferences! 🌍💡 #ConferenceSpeaker #ChemistryWorldConference #InternationalConference #ResearchInnovation.

✅🧠 Here are eight insights that align with the experiences of individuals, such as myself, who are enthusiastic about navigating a career that bridges both academia and industry.

🟩🟥 Exploring the intersection of academia and industry, I've gleaned valuable insights from Prof. Harvey Lodish. ✅ Here are eight lessons that resonate with those, like me, passionate about navigating a hybrid career in both environments. "Driving scientific progress hinges on providing insightful mentorship to a unique cohort of highly educated, innovative, and driven scientists." “Cloning the Epo receptor and later cloning the TGF-b receptors were risky ventures with no guarantees of success. Consequently, it's not surprising that I didn't receive any grants from NIH to support these projects. In my lectures about the Epo receptor cloning, I used to display a slide titled 'Ten reasons why NIH wouldn't support the Lodish lab in cloning the Epo receptor.' The reasons included statements like 'Lodish lacks experience in the field,' 'No record of making radio-iodinated Epo or performing binding assays,' 'Expression cloning technology is unproven,' and 'Epo receptor has multiple subunits, making it challenging for expression cloning.' While these points were baseless, grant review panels then or now wouldn't approve an application with so many uncertainties.” - Harvey Lodish, MIT Professor, Whitehead Institute Founding Member, and contributor to the establishment of companies like Genzyme and Millennium Pharmaceuticals. https://lnkd.in/gqHMZRiW #ScientificMentorship #InnovationInScience #EducationEmpowers #MotivatedScientists #ResearchExcellence #STEMLeadership #KnowledgeElevation #TechInnovation #InspiringMinds #FutureScientificLeaders

🌟 Lipidica at Analytica 2024 in Munich 🔬 The conference took place in the second week of April in Munich and is traditionally part of the leading world trade fair analytica 2024, where the latest trends in laboratory technology, biotechnology and analytical chemistry are presented. This year, the fair was attended by 1,066 exhibitors and 34,000 visitors from all over the world! 🌏   During the conference, more than 180 lectures 👨🏫 were presented by leading experts covering the entire spectrum of modern analytical chemistry. There were, for example, lectures on the topic of innovations in chromatography by Michael Laemmerhofer, pitfalls in lipidomic analysis by Gerhard Liebisch, or issues of sample preparation by Robert Gurke.   Among the invited speakers was the representative of the Lipidica, a.s. 👏 Ondřej Peterka, who presented our findings from the beginning of research into the use of lipidomic analysis for the early detection of pancreatic cancer, through the founding of the company Lipidica, a.s. and the transfer of the methodology up to the current state, which is already very close to the launch of the clinical performance study of the lipidomic test (LDPC). 👍   Link to the conference/fair https://lnkd.in/eXPSSR7b Learn more about our method https://www.lipidica.com/   #Analytica2024 #analyticalchemistry #biotechnology #laboratorytechnology #LDPClipidomictest

Only 2 days until the highly anticipated Biophysical Summit! ⛰ Get ready to be inspired by our esteemed lineup of speakers who will delve into cutting-edge topics in biophysics and pharmaceutical development. Join us for these insightful talks: Brent Kendrick: Biophysics of sucrose-IL-1ra Interactions Pavel Ryzhov, PhD: Biophysical Characterization of Fundamental Protein Questions: Folding, Physiological Conformation and Post-Translational Modifications. John Carpenter: Adverse Immunogenicity of Protein Drugs: Roles for Aggregates/Particles and Inadequate Analytical Methods Arani Chanda: Therapeutic phosphorodiamidate morpholino oligonucleotides: Physical properties, solution structures, and folding thermodynamics Justin Hopkins: Characterization of AAV Thermal Stability and Formulation Considerations Ashley B.: Measuring non-Newtonian Proteins and Applying the WRM Correction Register now: https://lnkd.in/eTpxGSES We look forward to welcoming you to this enlightening event! 🌟 #BiophysicalSummit #KBI #AppliedPhotophysics

VARDA is playing a big role in helping us to uncover the secrets of µgravity. This game changing research is going to transform our lives...yield new ways to address cancer, neurodegenerative diseases, and other diseases that have a devastating impact on the quality of life for millions. This work will also transform Advanced Materials / Semiconductor industry. Helping the US maintain leadership and at the same time yielding a huge impact on societal wellbeing. https://lnkd.in/dcCf5432